Last reviewed · How we verify
TAMIBAROTENE
TAMIBAROTENE is a drug. It is currently FDA-approved (first approved 2005).
Tamibarotene is a small molecule that acts as a retinoic acid receptor beta agonist. It is being studied in clinical trials for various conditions, including Myelodysplastic Syndromes, Pancreatic Cancer, Acute Myeloid Leukemia, and Alzheimer's Disease.
At a glance
| Generic name | TAMIBAROTENE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma (PHASE2)
- Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome (PHASE3)
- Study of Tamibarotene in Patients With ADPKD (PHASE2)
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (PHASE2)
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome (PHASE2)
- Investigator-initiated Clinical Trial of MIKE-1 (PHASE1, PHASE2)
- Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia (PHASE1, PHASE2)
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAMIBAROTENE CI brief — competitive landscape report
- TAMIBAROTENE updates RSS · CI watch RSS
Frequently asked questions about TAMIBAROTENE
What is TAMIBAROTENE?
When was TAMIBAROTENE approved?
What development phase is TAMIBAROTENE in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing